The Conversation (0)
DiaMedica Inc. (TSXV:DMA) announced a development update on its lead product candidates, DM199 and DM204. The Company also announced it intends to expand the testing of DM199 in diabetic kidney disease patients while also developing DMDx, a companion diagnostic for kidney disease.
DiaMedica Inc. (TSXV:DMA) announced a development update on its lead product candidates, DM199 and DM204. The Company also announced it intends to expand the testing of DM199 in diabetic kidney disease patients while also developing DMDx, a companion diagnostic for kidney disease. DiaMedica is a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications.
Mr. Rick Pauls, President and CEO of DiaMedica explained:
We believe there is a significant need for more effective therapies for diabetes and diabetic kidney disease, particularly as the prevalence of these diseases rises. We look forward to further advancing the development of our programs for diabetes while expanding into diabetic kidney disease and other associated diseases with DM199.
Click here to view the full press release.